gsk-1070916
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01118611)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
AURKB inhibitor
AURKC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1- Mol. weight
- 507.64 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1090479 ↗
Also known as
- 4-(3-(4-n,n-dimethylcarbamylaminophenyl)-1-ethyl-1h-pyrazol-4-yl)-2-(3-(dimethylaminomethyl)phenyl)-1h-pyrrolo(2,3-b)pyridine
- gsk1070916
- gsk1070916
- gsk1070916
- gsk 1070916
- gsk-1070916
- gsk-1070916
- gsk-1070916
- gsk1070916a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01118611 | Phase 1 | Mar 1, 2010 | Cancer Research UK, University of Leeds |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Leeds | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1